Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults.

Next Previous
Search
Trial Profile

Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NDV 3 (Primary)
  • Indications Candidiasis; Staphylococcal infections
  • Focus Adverse reactions

Most Recent Events

  • 13 Dec 2012 Results published in Vaccine, according to a NovaDigm Therapeutics media release.
  • 21 May 2012 Actual end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
  • 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top